DE602004029651D1 - Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen - Google Patents
Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionenInfo
- Publication number
- DE602004029651D1 DE602004029651D1 DE602004029651T DE602004029651T DE602004029651D1 DE 602004029651 D1 DE602004029651 D1 DE 602004029651D1 DE 602004029651 T DE602004029651 T DE 602004029651T DE 602004029651 T DE602004029651 T DE 602004029651T DE 602004029651 D1 DE602004029651 D1 DE 602004029651D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- methods
- oncoscene
- artemisinine
- viruses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title abstract 3
- 229960004191 artemisinin Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 title 1
- 229930101531 artemisinin Natural products 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010008263 Cervical dysplasia Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000026735 cervix disease Diseases 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44674303P | 2003-02-12 | 2003-02-12 | |
| PCT/US2004/004067 WO2004071506A1 (en) | 2003-02-12 | 2004-02-12 | Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004029651D1 true DE602004029651D1 (de) | 2010-12-02 |
Family
ID=32869550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004029651T Expired - Lifetime DE602004029651D1 (de) | 2003-02-12 | 2004-02-12 | Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US7989491B2 (de) |
| EP (3) | EP2305243A1 (de) |
| CN (2) | CN1758905A (de) |
| AT (1) | ATE485039T1 (de) |
| CA (1) | CA2515761C (de) |
| DE (1) | DE602004029651D1 (de) |
| ES (1) | ES2353384T3 (de) |
| HK (1) | HK1083314A1 (de) |
| MX (1) | MXPA05008527A (de) |
| WO (1) | WO2004071506A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| ATE485039T1 (de) * | 2003-02-12 | 2010-11-15 | Univ Georgetown | Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen |
| US20110206636A1 (en) * | 2003-09-16 | 2011-08-25 | Kemin Foods, LLC | Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus |
| ES2245248B1 (es) * | 2004-06-09 | 2007-02-16 | Universidad De Salamanca | Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos. |
| CN1311832C (zh) * | 2005-01-12 | 2007-04-25 | 四川科伦药业股份有限公司 | 溴代二氢青蒿素的医药用途 |
| US20110166106A1 (en) * | 2008-06-17 | 2011-07-07 | Manfred Marschall | Artemisinin and derivatives thereof as antivirals |
| AP2984A (en) * | 2009-01-14 | 2014-09-30 | Lincoln Pharmaceutical Ltd | An arteether injection for treatment of malaria |
| US20100279976A1 (en) * | 2009-04-30 | 2010-11-04 | Shanghai Institutes For Biological Sciences, Cas | Use of artemisinin and its derivatives in cancer therapy |
| EP2289554A1 (de) * | 2009-07-31 | 2011-03-02 | Dafra Pharma N.V. | Zusammensetzungen enthaltend Thalidomid und Artemisinin für die Krebsbehandlung |
| US8883765B2 (en) * | 2009-12-08 | 2014-11-11 | The John Hopkins University | Anti-cytomegalovirus activity of artemisinin-derived dimers |
| TWI482621B (zh) | 2009-12-23 | 2015-05-01 | Sigma Tau Ind Farmaceuti | 青蒿素基藥物與其他化學治療劑的抗癌組合物 |
| US9616067B2 (en) | 2012-04-18 | 2017-04-11 | Hadasit Medical Research Services And Development Ltd. | Methods and compositions for treating viral infections |
| CN102755316A (zh) * | 2012-07-16 | 2012-10-31 | 中国科学院武汉病毒研究所 | 青蒿素及其衍生物在制备治疗丙型肝炎病毒药物中的应用 |
| CN105142631A (zh) * | 2013-01-14 | 2015-12-09 | 健康诊所有限公司 | 抗癌药物和用途 |
| FR3008695B1 (fr) | 2013-07-16 | 2021-01-29 | Corning Inc | Verre aluminosilicate dont la composition est exempte de metaux alcalins, convenant comme substrat de plaques de cuisson pour chauffage a induction |
| US9918972B2 (en) * | 2014-12-23 | 2018-03-20 | The University Of Maryland, Baltimore | Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents |
| CN104906558B (zh) * | 2015-07-08 | 2016-11-16 | 广东天普生化医药股份有限公司 | 治疗宫颈癌的含有乌司他丁的药物组合物 |
| GB201805665D0 (en) * | 2018-04-05 | 2018-05-23 | Univ Nottingham | Antiviral Compounds And Methods |
| WO2019232129A1 (en) * | 2018-05-30 | 2019-12-05 | The Board Of Regents Of The University Of Texas System | Treatment of viral infections and virally associated lesions with sequiterpene lactones |
| CN110507819B (zh) * | 2019-08-13 | 2021-02-19 | 华南农业大学 | 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用 |
| WO2021186396A2 (en) * | 2020-03-18 | 2021-09-23 | Oncotelic Inc. | Tgf-beta inhibition, agents and composition therefor |
| MX2022011885A (es) * | 2020-03-26 | 2022-10-21 | Shin Poong Pharmaceutical Co Ltd | Composicion farmaceutica para la prevencion o tratamiento de enfermedad infecciosa viral de arn epidemica. |
| US20230233520A1 (en) * | 2020-04-23 | 2023-07-27 | Georgetown University | Combination therapy of artemisinin-related compounds and histone deacetylase inhibitors for treatment of hpv-related benign, premalignant, and malignant diseases |
| CA3184221A1 (en) * | 2020-06-26 | 2021-12-30 | Tien Canh Le | Water-soluble artesunate-based therapy for coronavirus infection |
| CN112294795B (zh) * | 2020-11-17 | 2022-03-29 | 北京化工大学 | 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用 |
| WO2023090947A1 (ko) * | 2021-11-18 | 2023-05-25 | 주식회사 노브메타파마 | 코로나바이러스 감염 질환의 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225554A (en) * | 1986-12-18 | 1993-07-06 | Sri International | Polyoxa tetracyclic compounds |
| US4916204A (en) | 1987-07-31 | 1990-04-10 | Massachusetts Institute Of Technology | Pure polyanhydride from dicarboxylic acid and coupling agent |
| US5219880A (en) * | 1991-03-29 | 1993-06-15 | Dermatologic Research Corporation | Treatment of viral tumors and hemorrhoids with artemisinin and derivatives |
| CN1051451C (zh) | 1992-11-10 | 2000-04-19 | 李泽琳 | 抗aids病毒的药物组合物 |
| CN1105238A (zh) | 1992-11-10 | 1995-07-19 | 中国预防医学科学院病毒学研究所 | 抗aids病毒的药物组合物 |
| US5726203A (en) | 1993-07-19 | 1998-03-10 | Li; Zelin | Qinghaosu derivatives against AIDS |
| US5409938A (en) * | 1994-02-14 | 1995-04-25 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof |
| US5639761A (en) * | 1994-02-14 | 1997-06-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof |
| US5578637A (en) * | 1995-05-03 | 1996-11-26 | University Of Washington | Methods of inhibition or killing cancer cells using an endoperoxide |
| US5677468A (en) * | 1995-06-29 | 1997-10-14 | Hauser, Inc. | Artemisinin dimer compounds having anticancer activity |
| US6160004A (en) * | 1997-12-30 | 2000-12-12 | Hauser, Inc. | C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities |
| US6297272B1 (en) * | 1999-01-12 | 2001-10-02 | Hauser, Inc. | Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same |
| WO2001042467A2 (en) * | 1999-12-08 | 2001-06-14 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| IL150286A0 (en) | 1999-12-30 | 2002-12-01 | Henderson Morley Res & Dev Ltd | Treatment of dna viral infections |
| EP1242096B1 (de) | 1999-12-30 | 2005-10-12 | Henderson Morley Research and Development Limited | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten |
| GB0005382D0 (en) | 2000-03-06 | 2000-04-26 | Henderson Morley Res & Dev Ltd | Pharmaceutical composition |
| EP1322316B1 (de) | 2000-09-21 | 2009-07-01 | Henderson Morley Research and Development Limited | Diuretikum oder sulfonylharnstoff zur benutzung in antiviraler behandlung |
| WO2002069949A2 (en) * | 2001-03-06 | 2002-09-12 | Prendergast Patrick T | Combination therapy for reduction of toxycity of chemotherapeutic agents |
| US20040115651A1 (en) * | 2002-12-12 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of BUB3 expression |
| NZ537113A (en) * | 2002-06-06 | 2007-01-26 | Univ Washington | Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer |
| US7842719B2 (en) | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| ATE485039T1 (de) * | 2003-02-12 | 2010-11-15 | Univ Georgetown | Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen |
| US20100178364A1 (en) * | 2009-01-12 | 2010-07-15 | Hanan Polansky | Dietary supplements against latent foreign DNA |
-
2004
- 2004-02-12 AT AT04710592T patent/ATE485039T1/de not_active IP Right Cessation
- 2004-02-12 MX MXPA05008527A patent/MXPA05008527A/es not_active Application Discontinuation
- 2004-02-12 EP EP20100183629 patent/EP2305243A1/de not_active Withdrawn
- 2004-02-12 WO PCT/US2004/004067 patent/WO2004071506A1/en active Application Filing
- 2004-02-12 EP EP17159205.8A patent/EP3257509A1/de not_active Ceased
- 2004-02-12 CN CNA2004800065000A patent/CN1758905A/zh active Pending
- 2004-02-12 DE DE602004029651T patent/DE602004029651D1/de not_active Expired - Lifetime
- 2004-02-12 EP EP04710592A patent/EP1594491B1/de not_active Expired - Lifetime
- 2004-02-12 CA CA2515761A patent/CA2515761C/en not_active Expired - Lifetime
- 2004-02-12 CN CN2013102238575A patent/CN103393672A/zh active Pending
- 2004-02-12 US US10/545,356 patent/US7989491B2/en active Active
- 2004-02-12 ES ES04710592T patent/ES2353384T3/es not_active Expired - Lifetime
-
2006
- 2006-05-12 HK HK06105509.7A patent/HK1083314A1/xx not_active IP Right Cessation
-
2011
- 2011-07-11 US US13/179,978 patent/US8394849B2/en not_active Expired - Lifetime
-
2013
- 2013-02-26 US US13/777,244 patent/US8940787B2/en not_active Expired - Lifetime
-
2015
- 2015-01-26 US US14/605,499 patent/US20150196530A1/en not_active Abandoned
-
2016
- 2016-10-13 US US15/292,511 patent/US20170246145A1/en not_active Abandoned
-
2018
- 2018-10-05 US US16/152,686 patent/US20190269648A1/en not_active Abandoned
-
2020
- 2020-10-16 US US17/072,726 patent/US20210038565A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170246145A1 (en) | 2017-08-31 |
| CN1758905A (zh) | 2006-04-12 |
| ATE485039T1 (de) | 2010-11-15 |
| ES2353384T3 (es) | 2011-03-01 |
| US20130296411A1 (en) | 2013-11-07 |
| MXPA05008527A (es) | 2006-03-08 |
| US8940787B2 (en) | 2015-01-27 |
| EP1594491A1 (de) | 2005-11-16 |
| US20070142459A1 (en) | 2007-06-21 |
| US20190269648A1 (en) | 2019-09-05 |
| US20120010278A1 (en) | 2012-01-12 |
| CA2515761C (en) | 2013-04-23 |
| HK1083314A1 (en) | 2006-06-30 |
| EP2305243A1 (de) | 2011-04-06 |
| CN103393672A (zh) | 2013-11-20 |
| US7989491B2 (en) | 2011-08-02 |
| EP1594491B1 (de) | 2010-10-20 |
| WO2004071506A1 (en) | 2004-08-26 |
| US20210038565A1 (en) | 2021-02-11 |
| US20150196530A1 (en) | 2015-07-16 |
| US8394849B2 (en) | 2013-03-12 |
| CA2515761A1 (en) | 2004-08-26 |
| EP3257509A1 (de) | 2017-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004029651D1 (de) | Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen | |
| CY1113038T1 (el) | Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου | |
| EA200700243A1 (ru) | Способы лечения гепатита с | |
| EA200600582A1 (ru) | Способы и композиции для лечения вирусного гепатита с | |
| DK1450799T3 (da) | Arylurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere | |
| ATE422358T1 (de) | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen | |
| WO2018209194A3 (en) | Newcastle disease viruses and uses thereof | |
| DE602006014843D1 (de) | Verwendung von hif 1alfa modulatoren zur behandlung von krebs | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| ATE519862T1 (de) | Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs | |
| ATE402713T1 (de) | Genetisch manipulierte herpesviren zur behandlung von tumoren | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| ATE526031T1 (de) | Antisekretorisches protein zur verwendung bei der behandung von kompartiment-syndrom | |
| DK1368054T3 (da) | Anvendelse af neurale trådproteiner til behandling af tumorer | |
| ATE478076T1 (de) | Azaxanthonen zur behandlung von tumoren | |
| DE602005007471D1 (de) | Satraplatin zur behandlung von resistenten oder refrkatären tumoren | |
| UA90477C2 (ru) | Способ лечения гепатита с (варианты) | |
| AU2003234342A8 (en) | Ablated slam-dependent entry | |
| ATE545423T1 (de) | Mittel zur behandlung von lungenkrebs | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| ATE386748T1 (de) | Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen | |
| BRPI0416390A (pt) | combinações para o tratamento de doenças proliferativas | |
| EA201992687A1 (ru) | Вирусы болезни ньюкасла и их применение | |
| ATE100318T1 (de) | Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren. | |
| ATE411313T1 (de) | Neue makrocyclen zur behandlung von krebserkrankungen |